AI Company Rescues Failed Drugs to Save Lives

Every year, pharmaceutical companies abandon promising drugs after safety concerns derail clinical trials, wasting billions of dollars and years of research. Now a Cambridge-based company called Ignota Labs is using artificial intelligence to give these failed drugs a second life.

Founded in 2021 by three scientists passionate about drug safety, Ignota Labs analyzes why drugs failed and re-engineers them to overcome toxicity problems. In February 2025, the company closed a $6.9 million funding deal and has since built a pipeline of promising treatments for autoimmune diseases and blood cancers.

Layla Hosseini-Gerami, the company's chief data science officer, leads the effort to understand how drugs affect the body. Her journey into AI-driven drug discovery started in 2016 during an internship where she built models to predict how molecules would behave in the body.

During her PhD at Cambridge, Hosseini-Gerami developed algorithms that identify how drugs work at a biological level. This research caught the attention of Jordan Lane and Sam Windsor, who saw an opportunity to tackle one of medicine's biggest inefficiencies.

Less than 10% of drug candidates make it through clinical trials successfully. Many fail because of safety concerns that appear only during animal studies or human trials, leading companies to abandon years of work and investment.

The Ignota Labs team realized these abandoned drugs often contain valuable science worth saving. By understanding exactly why a drug causes problems, they can redesign the molecule to eliminate toxicity while preserving its therapeutic benefits.

Hosseini-Gerami was recognized on Forbes magazine's '30 under 30' list in April 2025 for her work using AI to accelerate safe drug development. Her combination of chemistry, bioinformatics, and data science helps bridge the gap between laboratory discovery and real-world medicine.

The Ripple Effect

The impact of rescuing failed drugs extends far beyond individual treatments. This approach reduces the environmental footprint of drug development, which consumes enormous amounts of energy and water. It also decreases reliance on animal testing by learning from past experiments rather than starting from scratch.

The company emerged during a challenging period for biotech startups, when venture capital funding dried up after the COVID-19 pandemic. To succeed, the team had to clearly explain complex AI concepts to investors and demonstrate both strong science and commercial viability.

Now Ignota Labs can point to concrete results: a growing pipeline of rescued drugs and partnerships with major corporations. Their work proves that failure doesn't have to be final in drug development.

Every rescued drug represents hope for patients waiting for treatments that might have been lost forever. By turning past failures into future medicines, Ignota Labs is making the impossible possible.